, April 13, 2010

Pfizer recently became the latest big drug maker to start disclosing payments to doctors who act as consultants or speakers. But many followers of the pharmaceutical industry are still finding it far too difficult to follow the money, the New York Times reports. Industry bloggers and advocates for disclosure say the companies' Web sites are not easy enough to use for patients or others who want to know which doctors are most financially entwined with drug makers.

Facebook icon
LinkedIn icon
Twitter icon